RxDoctor Payments Data

Drew Crawford

Optometrist · Muskogee, OKNPI 1699021543

Payments from drug & device makers

$581in general payments, 2019–2025

Across 30 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$361
  • AbbVie$66
  • Sun Pharmaceutical Industries Inc.$42
  • Aerie Pharmaceuticals, Inc.$24
  • Quidel Corporation$22
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$21
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$581 in reported general payments places this provider in the 50th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$211,872
Medicare patients
1,027
Services billed
2,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine54$50,872
LumiganBimatoprost65$27,185
Prednisolone Acetate647$19,468
XiidraLifitegrast15$15,569
Ketorolac Tromethamine423$10,440
MieboPerfluorohexyloctane/Pf12$8,632
RocklatanNetarsudil Mesylat/Latanoprost11$6,895
VyzultaLatanoprostene Bunod14$6,311
SimbrinzaBrinzolamide/Brimonidine Tart27$5,360
Ofloxacin414$5,213
Latanoprost257$2,894
Alphagan PBrimonidine Tartrate13$2,621
Travoprost17$1,996
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$1,513
Brimonidine Tartrate183$1,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$66$80,678132 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$20$30,51241 claims
Aerie Pharmaceuticals, Inc.Rocklatan$24$6,89511 claims
AlconSimbrinza$361$5,36027 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$21$1,19211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Muskogee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →